Healthcare Industry News: Royal Philips
News Release - October 30, 2007
Calypso(R) Medical Announces Launch of Connectivity Product with Philips Pinnacle and Varian Eclipse Systems at the American Society of Therapeutic Radiology (ASTRO) 49th Annual MeetingLOS ANGELES--(HSMN NewsFeed)--Calypso Medical announces the launch of the first co-developed product for treatment planning system connectivity between the Calypso® 4D Localization System™ and Philips Medical and Varian Medical treatment planning systems. Calypso Medical’s new Workflow Efficiency release enables transfer of data from Philips Pinnacle³ and Varian Eclipse treatment planning systems to the Calypso System. These works-in-progress software features enhance workflow throughput between the treatment planning and delivery systems. Product delivery is expected to occur the first quarter of Y2008. This important upgrade will be showcased by Calypso Medical at the ASTRO 49th Annual Meeting to be held at the Los Angeles Convention Center from October 28-31.
Eric R. Meier, president and chief executive officer, observes, “With Philips Medical and Varian Medical Systems, we can provide the ‘missing link’ to advance radiation treatment workflow. Our proprietary AC electromagnetic technology enables unparalleled pinpoint tumor targeting, continuously, throughout the treatment process. Streamlining the radiation treatment workflow by interfacing directly with the Philips Pinnacle³ and Varian Eclipse treatment planning systems brings improved efficiency from the two largest providers of treatment planning systems.”
Calypso Medical intends to continue developing new products with Philips Medical and Varian Medical Systems to provide clinicians new options for patient positioning and the ability to manage organ motion throughout treatment delivery.
“Philips Radiation Oncology Systems and Calypso Medical have mutual customers who will benefit from this treatment planning connectivity. We believe this is a critical step in streamlining the radiation therapy workflow and this product launch establishes a foundation from which we intend to advance adaptive radiation therapy techniques that incorporate organ motion management,” states Keith Tipton, General Manager, Philips Radiation Oncology Systems.”
“Varian’s commitment to relationships such as this connectivity collaboration between Varian and Calypso Medical supports innovative radiation therapy operational advantages for the clinician,” said Karla Knott, senior director of marketing for Varian’s Oncology Systems business. “Ultimately, the interface collaboration between the Varian Eclipse Treatment Planning System and the Calypso System provides a more efficient and streamlined workflow for users of the Calypso System.”
The Calypso® 4D Localization System and implanted Beacon® electromagnetic transponders are designed to provide an accurate, objective, and continuous method to patient setup and continuously monitor the tumor target during radiation therapy. Calypso Medical’s commitment to improving cancer patient care is strengthened by working together with leading radiation therapy providers such as Philips Medical and Varian Medical Systems. Highly conformal radiation therapy treatment demands continuous knowledge of the exact location of the target throughout treatment delivery. The Calypso System can work in tandem with other product platforms to ensure that pinpoint accuracy is maintained continuously during the treatment process.
About Calypso® Medical
Calypso Medical Technologies, Inc. (“Calypso”) is a Seattle, WA-based privately held medical device company. The Company’s proprietary tumor localization system utilizes miniaturized implanted devices (Beacon® electromagnetic transponders) to continuously, accurately, and objectively pinpoint the location of tumors for improved accuracy in radiation therapy. Calypso addresses two major issues in modern radiation oncology: errors in treatment set-up and tumor motion during treatment. In addition, the Calypso® 4D Localization System’s non-ionizing electromagnetic guidance has been found to improve work flow efficiency and treatment room utilization. The technology is designed for body-wide cancers commonly treated with radiation therapy, including prostate, breast, lung, head, neck and other radiation therapy target organs. The products are FDA 510(k) cleared for use in the prostate only.
Calypso®, Beacon®, GPS for the Body®, Motion Matters™, Nothing Tracks Like the Beacon™, Calypso Within™, Beacon Within™, 4D Console™, 4D Electromagnetic Array™, 4D Tracking Station™, On Target, On With Living™ and/or other Calypso Medical Technologies, Inc.’s products referenced herein are either registered trademarks or trademarks in use of Calypso Medical Technologies, Inc. The names of actual companies and products mentioned herein may be the trademarks of their respective owners. Any rights not expressly granted herein are reserved.
About Royal Philips Electronics
Royal Philips Electronics of the Netherlands (NYSE: PHG, AEX: PHI) is a global leader in healthcare, lighting and consumer lifestyle, delivering products, services and solutions through the brand promise of “sense and simplicity.” Headquartered in the Netherlands, Philips employs approximately 128,100 employees in more than 60 countries worldwide. With sales of EUR 27 billion in 2006, the company is a market leader in medical diagnostic imaging and patient monitoring systems, energy efficient lighting solutions, personal care and home appliances, as well as consumer electronics. News from Philips is located at www.philips.com/newscenter.
Source: Calypso Medical Technologies
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.